Related Experiment Video
Updated: Dec 11, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Role of imaging biomarkers in mutation-driven non-small cell lung cancer
Dexter P Mendoza1, Zofia Piotrowska2, Jochen K Lennerz3
1Division of Thoracic Imaging and Intervention, Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, United States.
Abstract:
Lung cancer remains the leading cause of cancer-related deaths worldwide. The treatment of non-small cell lung cancer (NSCLC), which accounts for a vast majority of lung cancers, has shifted to personalized, targeted therapy following discoveries of several targetable oncogenic mutations. Targeting of specific mutations has improved outcomes in many patients. This success has led to several target-specific agents replacing chemotherapy as first-line treatment in certain mutated NSCLC. Several researchers have reported that there may be imaging biomarkers that may be predictive of the presence of these mutations. These features, when present, have the potential in triaging patients into the most appropriate diagnostic and treatment algorithms. Distinct imaging features and patterns of metastases that have been associated with NSCLC with various targetable oncogenic mutations are presented in this review.
Insights
Imaging biomarkers may predict targetable mutations in non-small cell lung cancer (NSCLC). These imaging features can help guide patient diagnosis and treatment for improved outcomes in NSCLC care.
Area of Science:
- Oncology
- Radiology
- Genomics
Background:
- Lung cancer is a leading cause of cancer mortality globally.
- Non-small cell lung cancer (NSCLC) treatment is increasingly personalized, focusing on targetable oncogenic mutations.
- Targeted therapies have improved outcomes for many NSCLC patients.
Purpose of the Study:
- To review distinct imaging features and metastasis patterns associated with NSCLC harboring targetable oncogenic mutations.
- To explore the potential of imaging biomarkers in predicting these mutations.
- To discuss how imaging can aid in triaging patients for appropriate diagnostic and treatment pathways.
Main Methods:
- Review of existing literature on imaging biomarkers and oncogenic mutations in NSCLC.
- Analysis of reported imaging features and metastasis patterns.
- Correlation of imaging findings with specific targetable mutations.
Main Results:
- Certain imaging features and metastasis patterns are associated with specific targetable mutations in NSCLC.
- These imaging biomarkers show potential for predicting the presence of targetable mutations.
- The identified features can assist in patient stratification for personalized medicine.
Conclusions:
- Imaging biomarkers may play a crucial role in identifying NSCLC patients with targetable mutations.
- Utilizing these biomarkers can optimize diagnostic and treatment algorithms.
- This approach supports the advancement of personalized therapy in NSCLC.
More Related Videos
08:14MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018